MERZ Pharma Canada Inc. is pleased to announce that effective May 19th 2011, XEOMIN(R) (clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins) has been listed with Limited Use Status on the Ontario Drug Benefit formulary (ODB).

For distribution to healthcare professionals only

TORONTO, May 19 /CNW/ - The Government of Ontario has recommended that Xeomin® be listed with Limited Use Status on ODB based on the following clinical criteria:

    LU Code 130 - To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.
    LU Code 421 - For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults.
    LU Authorization period: 1 year

Xeomin should be administered personally by a neurologist or a physician with equivalent post-graduate training and experience with neuromuscular disorders.

Trade name:   Xeomin®
Proper name:   Clostridium Botulinum Neurotoxin Type A (150 kD), free from complexing proteins
Manufacturer: Merz Pharmaceuticals GmbH
Dosage form:   Powder for intramuscular injection
Strength:   100 units

About Xeomin®
Xeomin® is a neurotoxin therapy, free from complexing proteins, that combines high specific biologic activity with low bacterial protein load. It has been approved for marketing in Europe since 2005 to treat various movement disorders, and more recently was approved in Canada for the treatment of hypertonicity disorders of the 7th nerve such as blepharospasm including benign essential blepharospasm and hemifacial spasm in adults. To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults and for the treatment of upper limb spasticity associated with stroke in adults.

About Merz
Merz Pharma Canada Ltd, a wholly owned subsidiary of the Merz Pharma Group of Companies was established in 2009 to commercialize Xeomin® and expand other Merz franchises in the Canadian marketplace.

Merz Pharmaceuticals GmbH (
Merz Pharmaceuticals, a member of the Merz Pharma Group of companies, is an innovative and international healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Merz is a leader in the field of neurology. In addition to developing Xeomin®, the company has developed memantine (Axura®) -- the first drug with a unique mechanism of action that focuses on the glutamatergic system for the treatment of moderate to severe Alzheimer's disease. The company also focuses on the development of innovative therapies within the therapeutic areas of hepatology, metabolic disease and dermatology.



SOURCE Merz Pharma Canada Ltd

For further information:

Glenn Block, President and General Manager (905)-315-1193

Profil de l'entreprise

Merz Pharma Canada Ltd

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.